Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108995&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on Orthofix Medical Inc. (OFIX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or the "Company") (NASDAQ:OFIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Orthofix Medical Inc. - OFIX

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108962&wire=1 or contact Joseph E. Levi, Esq.

Orthofix Medical Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights - OFIX

LOS ANGELES , Oct. 21, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ: OFIX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 11, 2022, and September 12, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2024.

OFIX Investors Have Opportunity to Lead Orthofix Medical Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108904&wire=1 or contact Joseph E. Levi, Esq.

Orthofix Medical Inc. Class Action: Levi & Korsinsky Reminds Orthofix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - OFIX

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference in New York. Management is scheduled to present on Monday, November 18, 2024 at 8:35 am ET. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.com. Internet Po.

Orthofix to Participate in Stifel 2024 Healthcare Conference

NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108854&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Orthofix Medical Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights - OFIX

NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108824&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in Orthofix Medical Inc. Lawsuit - OFIX

LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 11, 2022, and September 12, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2024.

The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Orthofix Medical Inc.

LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 11, 2022, and September 12, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2024.

Orthofix Medical Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Help The Schall Law Firm

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Orthofix To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Orthofix between October 11, 2022, and September 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 19, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Orthofix Medical Inc. ("Orthofix" or the "Company") (NASDAQ: OFIX) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Orthofix

NEW YORK, Oct. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Orthofix Medical Inc. (NASDAQ: OFIX) between October 11, 2022 and September 12, 2023, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline.

RLF, SKILLED INVESTOR COUNSEL, Encourages Orthofix Medical Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – OFIX

LOS ANGELES , Oct. 18, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Orthofix Medical Inc. ("Orthofix" or the "Company") (NASDAQ: OFIX). Class Period: October 11, 2022 – September 12, 2023 Lead Plaintiff Deadline: October 21, 2024 If you wish to serve as lead plaintiff of the Orthofix lawsuit, you can submit your contact information at www.glancylaw.com/cases/Orthofix-Medical-Inc/.

OFIX Investors Have Opportunity to Lead Orthofix Medical Inc. Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) common stock between October 11, 2022 and September 12, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On September 12, 2023, before the market opened,.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orthofix Medical Inc. (OFIX)

LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 11, 2022, and September 12, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2024.

Orthofix Medical Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

NEW YORK , Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Orthofix Medical Inc. (NASDAQ: OFIX). Shareholders who purchased shares of OFIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies Shareholders of Orthofix Medical Inc.(OFIX) of a Class Action Lawsuit and an Upcoming Deadline

NEW ORLEANS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 21, 2024 to file lead plaintiff applications in a securities class action lawsuit against Orthofix Medical, Inc. (NasdaqGS: OFIX), if they purchased the Company's shares between October 11, 2022, and September 12, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Texas.

ORTHOFIX MEDICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orthofix Medical, Inc. - OFIX

NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108808&wire=1 or contact Joseph E. Levi, Esq.

October 21, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against OFIX

NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108792&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Orthofix Medical Inc. (OFIX) - October 21, 2024 Deadline to Join - Contact Levi & Korsinsky

Robbins LLP is Investigating Allegations that Orthofix Medical Inc. (OFIX) Misled Investors in Connection with its Acquisition of SeaSpine Holdings Corp.

OFIX Investors: If You Sustained Significant Losses in Orthofix Medical Inc. Contact Shareholder Rights Law Firm Robbins LLP for Information About the Pending Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108779&wire=1 or contact Joseph E. Levi, Esq.

Investors who Lost Money on Orthofix Medical Inc. (OFIX) Should Contact Levi & Korsinsky About Pending Class Action - OFIX

LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) common stock between October 11, 2022 and September 12, 2023, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orthofix Medical Inc. (OFIX)

NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/orthofix-lawsuit-submission-form?prid=108739&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on Orthofix Medical Inc. (OFIX) Should Contact Levi & Korsinsky About Pending Class Action - OFIX

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Orthofix Medical, Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) on behalf of purchasers of Orthofix securities between October 11, 2022 and September 12, 2023, inclusive (the “Class Period”) .

DEADLINE NEXT WEEK: Berger Montague Advises Orthofix Medical (NASDAQ: OFIX) Investors to Contact the Firm Before October 21, 2024

NEW YORK CITY, NY / ACCESSWIRE / October 16, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class").

News for Orthofix International Stock (OFIX)